CD274 and neoplasm: The expression of PD-L1 (54), tumor mutational burden (TMB) (55), specific gene mutations, tumor-infiltrating lymphocytes (TIL) (56), antigen presentation defects (57), and gene expression profiles (GEPs) (58) could be used as predictive biomarkers of immunotherapy efficacy.